Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$220 Mln
P/E Ratio
--
P/B Ratio
2.05
Industry P/E
--
Debt to Equity
0.01
ROE
-0.3 %
ROCE
-25.98 %
Div. Yield
0 %
Book Value
--
EPS
--
CFO
A$-159.49 Mln
EBITDA
A$-235.03 Mln
Net Profit
A$-261.37 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Immutep - ADR
| -25.35 | -13.83 | -17.35 | -30.17 | -10.90 | 10.57 | -2.56 |
|
BSE Sensex*
| 1.99 | 3.77 | 4.29 | 8.22 | 11.74 | 20.16 | 11.15 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Immutep - ADR
| -9.51 | 37.14 | -46.65 | 4.46 | 75.42 | -2.72 | 17.10 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Immutep Limited, a late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alpha (efti or IMP321), a soluble LAG-3lg... fusion based, which is in clinical development for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. In addition, it develops INSIGHT-003, which is in phase I to treat 1L NSCLC and solid tumors; INSIGHT-005, which is in phase I to treat metastatic urothelial cancer; IMP761, which is in preclinical trial to treat autoimmune disease; and IMP731 and IMP701 which is in clinical development. Further, the company develops LAG525, which is in phase II clinical trial to treat solid tumors and blood cancer, triple negative breast cancer, and melanoma; and in phase I to treat triple negative breast cancer. Immutep has collaboration with Merck & Co., Inc., GlaxoSmithKline, EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia. Address: Australia Square, Sydney, NSW, Australia, 2000 Read more
CEO, MD, CFO, Chief Business Officer & Executive Director
Mr. Marc Voigt
CEO, MD, CFO, Chief Business Officer & Executive Director
Mr. Marc Voigt
Headquarters
Sydney, NSW
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Immutep Limited - ADR stood at $ 202 Mln as on 30-Jun-24
The share price of Immutep Limited - ADR is $1.62 (NASDAQ) as of 23-Apr-2025 16:02 EDT. Immutep Limited - ADR has given a return of -10.9% in the last 3 years.
Immutep Limited - ADR has a market capitalisation of $ 220 Mln as on 22-Apr-2025. As per Value Research classification, it is a company.
Since, TTM earnings of Immutep Limited - ADR is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Immutep Limited - ADR and enter the required number of quantities and click on buy to purchase the shares of Immutep Limited - ADR.
Immutep Limited, a late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alpha (efti or IMP321), a soluble LAG-3lg fusion based, which is in clinical development for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. In addition, it develops INSIGHT-003, which is in phase I to treat 1L NSCLC and solid tumors; INSIGHT-005, which is in phase I to treat metastatic urothelial cancer; IMP761, which is in preclinical trial to treat autoimmune disease; and IMP731 and IMP701 which is in clinical development. Further, the company develops LAG525, which is in phase II clinical trial to treat solid tumors and blood cancer, triple negative breast cancer, and melanoma; and in phase I to treat triple negative breast cancer. Immutep has collaboration with Merck & Co., Inc., GlaxoSmithKline, EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia. Address: Australia Square, Sydney, NSW, Australia, 2000
The CEO & director of Mr. Marc Voigt. is Immutep Limited - ADR, and CFO & Sr. VP is Mr. Marc Voigt.
There is no promoter pledging in Immutep Limited - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Immutep Limited - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
-26.21
|
|
Operating margin(%)
|
-1211.84
|
|
Net Margin(%)
|
-1111.87
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Immutep Limited - ADR was $-19 Mln.
$0.09
(
